KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Notes Payables: 2024-2025

Historic Notes Payables for Neogenomics (NEO) over the last 1 years, with Mar 2025 value amounting to $201.1 million.

  • Neogenomics' Notes Payables was N/A to $201.1 million in Q1 2025 from the same period last year, while for Mar 2025 it was $201.1 million, marking a year-over-year change of. This contributed to the annual value of $200.8 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q1 2025, Neogenomics' Notes Payables is $201.1 million, which was up 0.18% from $200.8 million recorded in Q4 2024.
  • Neogenomics' 5-year Notes Payables high stood at $201.1 million for Q1 2025, and its period low was $200.1 million during Q2 2024.
  • Over the past 2 years, Neogenomics' median Notes Payables value was $200.6 million (recorded in 2024), while the average stood at $200.6 million.